Dr Winlo sounds very confident here and we can expect a busy...

Dr Winlo sounds very confident here and we can expect a busy next 12 months.

Emyria has been preparing for this for 2 years so what are the plans,
Activate private psychiatry practices so they can deliver this treatment that means being part of the daily infrastructure by helping with the

• Reporting requirements
• Safety monitoring
• Tracking of patient

These will be required for these specialists to obtain an authorised prescriber qualification

Next we can manage the supply chain for these practices as Emyria has the licenses and the network partners to handle this still heavily controlled/regulated drug

Last is to provide training for the therapists, I am sure this is obvious that these psychotherapy sessions will be considerably different and follow up and patient care will be incredibly important.

The Project Youtube video@1:40
"The cost of one of these treatments could be as much as $20,000 per patient" - Dr Stephen Bright

With all that said, it sounds like this could generate some serious short term revenue for the company.




What Michael proceeds to say next answered the question that was burning me all last week, the rescheduling opens up a registration pathway for our analogue program.
Near term we can expect decent news flow,

• Updates on partner networks/specialist providers
• Updates on the supply chain
• Advancements in therapy training
• Cannabinoid program phase 3 trial results
• Commercial partners for EMD-RX5
• Updates on prescription cannabinoid program(EMD-RX7)
• Updates on pre clinical MDMA program

Things will heat up when these announcements drop assuming they have direct impact on potential revenue.